期刊文献+

肠白塞病64例临床分析 被引量:17

Clinical analysis of gastrointestinal involvement in Behcet's disease: a study of 64 patients
原文传递
导出
摘要 目的探讨肠白塞病的临床特点。方法回顾性分析北京协和医院1994年1月至2013年8月肠白塞病住院患者临床资料,分析临床、实验室及内镜特点,并探讨性别对病情的影响。采用t检验或,检验进行统计学分析。结果肠白塞病患者64例,占同期白塞病住院患者10.5%(64/611),其中男性31例,女性33例。肠白塞病消化系统症状中位发病年龄34岁(5~71岁),91%(58例)患者消化系统症状出现在白塞病其他系统首发表现之后。临床以腹痛最常见(88%,56/64),部分患者可出现消化道出血(31%,20/64)、肠梗阻(22%,14/64)、肠穿孔(11%,7/64)、肠瘘(16%,10/64)等严重并发症。内镜下病变主要累及回盲部,以深大溃疡为主。女性肠白塞病患者CRP较男性高[(52±46)和(27±36)mg/L,t=2.287,P=0.026],血清白蛋白水平较低[(34±6)和(37±5)mg/L](t=2.237,P=0.029)。糖皮质激素联合免疫抑制剂及TNF-α拮抗剂治疗后;62例有效,共有21例次患者病程中有手术史。结论肠白塞病以青壮年患者多见,消化道症状多晚于白塞病系统病变出现,临床以腹痛最常见,病变主要累及回盲部,以深大溃疡为主,女性病情相对较重。激素联合免疫抑制剂治疗多有效,部分需要手术治疗。 Objective To investigate the clinic manifestations of intestinal involvement of Behqet's disease (BD). Methods Medical data of patients with intestinal involvement of BD admitted to Peking Union Medical College Hospital (PUMCH) from January 1994 to August 2013 were retrospectively reviewed. Clinic manifestations, laboratory tests and endoscopic characteristics were analyzed, and the influence of sex on the clinic manifestations was investigated. Numerical data and categorical data comparisons were analyzed using t-test, X^2test respectively. Results Sixty-four patients with intestinal involvement accounted for 10.5 percent (64/611) of total hospitalized BD patients during the same period. Among these 64 patients, 31 were male and 33 were female. The median age at the onset of intestinal involvement was 34 years old. Gastrointestinal symptoms were presented after other systemic symptoms of BD in 91% patients (58/64). Abdominal pain (88%, 56/64) was the most common clinical manifestations of intestinal involvement, and severe complications such as gastrointestinal bleeding (31%, 20/64), intestinal obstruction (22%, 14/64), intestinal perforation (11%, 7/64) and intestinal fistula (16%, 10/64) could also occur in some patients. Lesions usually located at ileocecum portion of the gastrointestinal tract. The common endoscopic manifestation was deep ulcers. Female sex was associated with higher C reactive protein level and lower serum albumin level [ (52±46) vs (27±36) rag/L, t=2.287, P=0.026; Serum albumin: (34±6) vs (37±5) mg/L, t=2.237, P=0.029 ]. After treated with glucocorticoid, im-munosuppressant and TNF-ct blockers, 62 patients achieved clinical remission while 21 cases were'operated. Conclusion Most of intestinal involvement of BD patients are young adults, and the gastrointestinal syrup-toms usually present after the presence of other systemic symptoms.Abdominal pain is the most common manifestations, while severe complications such as gastrointestinal bleeding and intestinal obstruction can also occur. The most common endoscopic findings are deep ulcers, which often located in the ileocecal region. Female patients are more likely to have severe clinical course. Glucocorticoid, immunosup-pressant and TNF-ct antagonist therapy are effective, but some patients still need surgical intervention.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2014年第8期515-519,共5页 Chinese Journal of Rheumatology
关键词 贝赫切特综合征 治疗 临床研究性 Behcet's syndrome Therapies, investigational
  • 相关文献

参考文献2

二级参考文献18

  • 1张士发,王良明,张海涛,顾苏宁.白塞氏病125例临床分析[J].皮肤病与性病,1996,18(4):8-9. 被引量:3
  • 2Naganuma M,Iwao Y,Inoue N,et al.Analysis of clinical course and long-term prognosis surgical and nonsurgical patients with intestinal Behcet's disease.Am J Gastroenterol,2000,95:2848-2851.
  • 3Sommer A,Altmeyer P,Kreuter A.A case of mucocutaneous Behcet's disease responding to etanercept.J Am Acad Dermatol,2005,52:717-719.
  • 4Hassard PV,Bider SW,Nelson V,et al.Anti-tumor necrosis factor monoclonal antiboby therapy for gastrointestinal Behcet's disease:a case report.Gastroenterology,2001,120:995-999.
  • 5Byeon JS,Choi EK,Heo NY,et al.Anti-tumor necrosis factoralpha therapy for early postoperative recurrence or gastrointestinal Behqet's disease:report of a case.Dis Colon Rectum,2007,50:672-676.
  • 6Ju JH,Kwon SK,Seo SH,et al.Successful treatment of lifethreatening intestinal ulcer in Behcet's disease with infliximab:rapid healing of Behqet's ulcer with infliximab.Clin Rheumatol,2007,26:1383-1385.
  • 7Naganuma M,Sakuraba A,Hisamatsu T,et al.Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease.Inflamm Bowel Dis,2008,14:1259-1264.
  • 8Iwata S,Saito K,Yamaoka K,et al.Effects of anti-TNF-α antibody infliximab in refractory entero-Behqet's disease.Rheumatology,2009,48:1012-1016.
  • 9Sfikakis PP,Markomichelakis N,Alpsoy E,et al.Anti-TNF therapy in the management of Behcet's disease:review and basis for recommendations.Rheumatology,2007,46:736-741.
  • 10Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med,2004, 4:10 - 20.

共引文献68

同被引文献68

引证文献17

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部